136 related articles for article (PubMed ID: 30134224)
1. Inhibition of Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ) Overcomes Drug Resistance and Tumorigenicity in Ovarian Cancer.
Hong L; Chen W; Xing A; Wu D; Wang S
Cell Physiol Biochem; 2018; 49(1):53-64. PubMed ID: 30134224
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer.
Li S; Cao J; Zhang W; Zhang F; Ni G; Luo Q; Wang M; Tao X; Xia H
Sci Rep; 2016 Nov; 6():36873. PubMed ID: 27833130
[TBL] [Abstract][Full Text] [Related]
3. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) enhances tumorigenesis both in vivo and in vitro in bladder cancer.
Liu S; Jiang H; Wen H; Ding Q; Feng C
Oncol Rep; 2018 May; 39(5):2127-2135. PubMed ID: 29512774
[TBL] [Abstract][Full Text] [Related]
5. YWHAZ promotes ovarian cancer metastasis by modulating glycolysis.
Shi J; Ye J; Fei H; Jiang SH; Wu ZY; Chen YP; Zhang LW; Yang XM
Oncol Rep; 2019 Feb; 41(2):1101-1112. PubMed ID: 30535456
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-185-5p targets tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta to regulate non-small cell lung cancer progression.
Ma J; Bai Y; Chen F; Zhou F; Zhang L; Xue P; Wang D
J Cardiothorac Surg; 2023 Jul; 18(1):241. PubMed ID: 37525284
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-802 suppresses proliferation and migration of epithelial ovarian cancer cells by targeting YWHAZ.
Yang B; Sun L; Liang L
J Ovarian Res; 2019 Oct; 12(1):100. PubMed ID: 31640760
[TBL] [Abstract][Full Text] [Related]
8. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Wang W; Zhang L; Wang Y; Ding Y; Chen T; Wang Y; Wang H; Li Y; Duan K; Chen S; Yang Q; Chen C
Cell Death Dis; 2017 Oct; 8(10):e3071. PubMed ID: 28981108
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
11. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
14. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
17. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
18. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
19. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
